Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?
Patients with myeloma who undergo autologous hematopoietic cell transplantation (AHCT) may experience a decline in health-related quality of life (HRQoL). Although exercise has been...
Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes
More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more
Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention
Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...
Number of Older Patients Receiving AlloHCT Increased Over the Past Decade
Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia
In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
Trial Roundup: PRTX-100 for Immune Thrombocytopenia, APR-246 for Myeloid Neoplasms, and more
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD
Dana-Farber Cancer Institute
A...
Examining Vorinostat to Prevent Graft-Versus-Host Disease After Unrelated Donor HCT
While the histone deacetylase (HDAC) inhibitor vorinostat led to a low incidence of acute graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT) with reduced-intensity...
Ruxolitinib Versus Best Available Therapy for Essential Thrombocythemia
Treatment with the JAK1/2 inhibitor ruxolitinib failed to improve response rates, compared with best-available therapy (BAT) in patients with essential thrombocythemia (ET) who were...
Investigating How Patients With Hemophilia Manage Pain
As the life expectancy of people with hemophilia has increased, patients are living longer with disease-associated pain, particularly in their joints. According to the...
Is Idarucizumab the First “Antidote” to a Direct Oral Anticoagulant?
Idarucizumab “rapidly and completely” reversed the blood-thinning effects of the direct oral anticoagulant dabigatran in patients who had uncontrolled bleeding or were about to...
Current Issue
September 2017, Volume 3, Issue 11
This issue features a look at efforts to include individuals with intellectual and developmental disabilities in clinical research, our new "How I Treat In Brief" section, and more.
